ADIONA Platform Launched Through Partnership Between Kahala Biosciences and Rymedi End-to-End Solution for Antibody Testing and Tracking Designed to Enable Americans to Safely Return to the Workplace
IRVINE, Calif. – May 16, 2020 – Kahala Biosciences LLC, an Irvine-based COVID-19 testing and tracking company, and technology partner Rymedi Inc., a Greenville, South Carolina-based developer of blockchain-based protocols and solutions for complex life sciences and pharmaceuticals, today announced the ADIONATM COVID-19 antibody testing platform, the first system available in the U.S. that integrates antibody testing with a blockchain-based smartphone software application to bring predictability and traceability to COVID-19 antibody testing.
Antibody testing is used to determine if someone has been previously infected with the COVID- 19 virus and may have developed immunity.